MO - Is Cronos Stock Worth Buying? Probably But Patience Remains A Requirement

• Cronos has taken a "slow and steady wins the race" approach to cannabis, with an obvious eye on a fully legalized American market.
• The case is slowly (and unevenly) playing out, with fermentation efforts progressing and the PharmaCann deal providing a first step into the U.S.
• At $8, CRON still looks attractive from a long-term perspective, but a key word there is "long-term."

For further details see: